Correction to Lancet Oncol 2015; 16: 522-30. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. - Suppr | 超能文献

Correction to Lancet Oncol 2015; 16: 522-30. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial.

作者信息

Eggermont A M M, Chiarion-Sileni V, Grob J-J

出版信息

Lancet Oncol. 2015 Jun;16(6):e262. doi: 10.1016/S1470-2045(15)70271-8. Epub 2015 May 27.

DOI:10.1016/S1470-2045(15)70271-8

Abstract

摘要

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1

Correction to Lancet Oncol 2015; 16: 522-30. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial.

Lancet Oncol. 2015 Jun;16(6):e262. doi: 10.1016/S1470-2045(15)70271-8. Epub 2015 May 27.

2

Correction to Lancet Oncol 2015; 16: 499-508. Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study.《柳叶刀·肿瘤学》2015年第16卷第499 - 508页的勘误。雷莫西尤单抗与安慰剂联合二线FOLFIRI用于在一线使用贝伐单抗、奥沙利铂和氟嘧啶治疗期间或之后进展的转移性结直肠癌患者（RAISE）：一项随机、双盲、多中心、3期研究。

Lancet Oncol. 2015 Jun;16(6):e262. doi: 10.1016/S1470-2045(15)70273-1. Epub 2015 May 27.

3

The current EORTC Melanoma Cooperative Group adjuvant trial programme on malignant melanoma: prognosis versus efficacy, toxicity and costs.欧洲癌症研究与治疗组织黑色素瘤协作组目前关于恶性黑色素瘤的辅助试验项目：预后与疗效、毒性及成本。

Melanoma Res. 1997 Aug;7 Suppl 2:S127-31.

4

Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial.特泽莫替尼（L-BLP25）联合放化疗对比安慰剂治疗 III 期非小细胞肺癌（START）：一项随机、双盲、III 期临床试验。

Lancet Oncol. 2014 Jan;15(1):59-68. doi: 10.1016/S1470-2045(13)70510-2. Epub 2013 Dec 9.

5

Adjuvant therapy with high dose vitamin D following primary treatment of melanoma at high risk of recurrence: a placebo controlled randomised phase II trial (ANZMTG 02.09 Mel-D).复发高风险黑色素瘤初次治疗后大剂量维生素D辅助治疗：一项安慰剂对照随机II期试验（ANZMTG 02.09 Mel-D）

BMC Cancer. 2014 Oct 24;14:780. doi: 10.1186/1471-2407-14-780.

6

Prospective, randomized, multicenter, double-blind placebo-controlled trial comparing adjuvant interferon alfa and isotretinoin with interferon alfa alone in stage IIA and IIB melanoma: European Cooperative Adjuvant Melanoma Treatment Study Group.前瞻性、随机、多中心、双盲安慰剂对照试验：比较辅助性干扰素α联合异维A酸与单用干扰素α治疗IIA期和IIB期黑色素瘤的疗效——欧洲黑色素瘤辅助治疗协作研究组

J Clin Oncol. 2005 Dec 1;23(34):8655-63. doi: 10.1200/JCO.2004.00.8128. Epub 2005 Oct 31.

7

Melanoma adjuvant therapy.黑色素瘤辅助治疗

Chin Clin Oncol. 2014 Sep;3(3):26. doi: 10.3978/j.issn.2304-3865.2014.03.02.

8

Correction to Lancet Oncol 2015; 16: 324. High-dose radiotherapy with shortterm or long-term androgen deprivation in localised prostate cancer (DART01/05 GICOR): a randomised, controlled, phase 3 trial.《柳叶刀·肿瘤学》2015年第16卷第324页的勘误。局限性前列腺癌高剂量放疗联合短期或长期雄激素剥夺治疗（DART01/05 GICOR）：一项随机对照3期试验。

Lancet Oncol. 2015 Jun;16(6):e262. doi: 10.1016/S1470-2045(15)70272-X. Epub 2015 May 27.

9

Immune checkpoint inhibitors in melanoma provide the cornerstones for curative therapies.黑色素瘤中的免疫检查点抑制剂为治愈性疗法奠定了基础。

Semin Oncol. 2015 Jun;42(3):429-35. doi: 10.1053/j.seminoncol.2015.02.010. Epub 2015 Feb 14.

10

Adjuvant ganglioside GM2-KLH/QS-21 vaccination versus observation after resection of primary tumor > 1.5 mm in patients with stage II melanoma: results of the EORTC 18961 randomized phase III trial.辅助神经节苷脂 GM2-KLH/QS-21 疫苗接种与 II 期黑色素瘤患者原发肿瘤切除后 > 1.5 毫米的观察比较：EORTC 18961 随机 III 期试验结果。

J Clin Oncol. 2013 Oct 20;31(30):3831-7. doi: 10.1200/JCO.2012.47.9303. Epub 2013 Sep 9.

引用本文的文献

1

Successful Targeting of CTLA-4 in a Melanoma Clinical Case: A Long-Term "One Stop Therapeutic Shop".成功靶向CTLA-4治疗黑色素瘤临床病例：长期的“一站式治疗方案”

Onco Targets Ther. 2022 Nov 25;15:1409-1415. doi: 10.2147/OTT.S367389. eCollection 2022.

2

Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline.免疫检查点抑制剂治疗患者免疫相关不良反应的管理：美国临床肿瘤学会临床实践指南。

J Clin Oncol. 2018 Jun 10;36(17):1714-1768. doi: 10.1200/JCO.2017.77.6385. Epub 2018 Feb 14.

3

My personal highlights of ESMO 2016.2016年欧洲肿瘤内科学会（ESMO）大会上我的个人亮点。

Memo. 2017;10(1):46-47. doi: 10.1007/s12254-017-0314-8. Epub 2017 Feb 8.